Zebrafish Glioblastoma (GBM) Models

Introduction Model Details Phenotypic Evaluation Applications Study Examples

Introduction

Glioblastoma (GBM) is the most aggressive malignant primary tumor of the central nervous system and is classified as a WHO grade 4 glioma. It is characterized by rapid proliferation, diffuse infiltration into surrounding brain tissue, marked angiogenesis, necrosis, genomic instability, and a highly immunosuppressive tumor microenvironment. Clinically, GBM often presents with headache, seizures, cognitive decline, focal neurological deficits, and symptoms related to increased intracranial pressure. The disease occurs mainly in adults, with higher incidence in older populations, and remains associated with poor prognosis despite intensive treatment.

Current standard-of-care therapy includes maximal safe surgical resection followed by radiotherapy and temozolomide-based chemotherapy. Molecularly guided therapies, anti-angiogenic agents, tumor-treating fields, and immunotherapies are also under active investigation. However, GBM research is challenged by profound inter- and intra-tumoral heterogeneity, invasive growth, blood–brain barrier limitations, therapy resistance, and limited predictive value of conventional in vitro assays. Zebrafish GBM models provide a complementary in vivo platform for rapid visualization of tumor growth, invasion, angiogenesis, microglia/macrophage interaction, and drug response in a vertebrate system.

Why Zebrafish?

Real-time imaging: Transparent larvae enable real-time imaging of intracranial tumor behavior.
Throughput: Small size supports rapid, medium-throughput drug evaluation.
Orthotopic transplantation: Allows assessment of brain-specific tumor invasion.
Reporter lines: Transgenic reporter lines enable visualization of vasculature and immune cells.
Immune compatibility: Early-stage larvae reduce barriers for xenograft studies without full immune rejection.

Available Zebrafish Disease Models

Model Name	Induction Method	Features
Orthotopic GBM Cell Line Xenograft Model	Fluorescently labeled human GBM cells, such as U87, U251, U373, LN229, or patient-derived GBM cells, are microinjected into the zebrafish larval brain.	Suitable for tumor growth, intracranial invasion, survival, and drug efficacy studies; compatible with live imaging and quantitative fluorescence analysis.
GBM Stem-like Cell / Gliomasphere Xenograft Model	GBM stem-like cells or gliomaspheres are injected into zebrafish embryos or larvae, commonly into the brain or perivitelline space.	Supports evaluation of invasive capacity, stemness-associated tumor behavior, therapy resistance, and candidate anti-invasive compounds.
Patient-Derived GBM Xenograft Model	Fresh or cultured patient-derived GBM cells are fluorescently labeled and transplanted into larval zebrafish.	Enables patient-relevant tumor growth and drug response assessment; useful for translational studies and personalized screening workflows.
Genetically Induced GBM-like Zebrafish Model	Neural expression of oncogenic drivers, such as EGFRvIII and PI3K pathway activation, often combined with tp53 deficiency.	Models tumor initiation and progression in an immunocompetent zebrafish background; useful for mechanism studies and pathway validation.

Phenotypic Evaluation

Drug Response and Safety

Reduction in tumor burden
Inhibition of invasion or angiogenesis
Larval survival and gross morphology
Basic toxicity readouts, such as edema or developmental delay

Tumor Invasion

Migration distance from injection site
Number of invasive tumor cell clusters
Brain tissue infiltration pattern

Tumor Microenvironment

Tumor-induced angiogenesis
Microglia/macrophage recruitment
Tumor–vessel or tumor–immune cell interaction

Tumor Growth

Tumor fluorescence area or intensity
Intracranial tumor expansion
Tumor growth inhibition after treatment

Key Applications

In vivo anti-GBM drug screening: Evaluate small molecules, biologics, and combination therapies.
Blood–brain barrier-penetrant compound assessment: Test BBB-penetrant compounds in orthotopic GBM settings.
Tumor invasion and migration studies: Use live imaging of labeled GBM cells to study invasion and migration.
Tumor angiogenesis evaluation: Evaluate tumor angiogenesis and anti-angiogenic strategies in vascular reporter lines.
Mechanistic studies of GBM–microenvironment interaction: Investigate macrophage/microglia recruitment and immune modulation.

Study Examples

This study established an orthotopic zebrafish GBM xenograft model by transplanting fluorescent human glioblastoma cell lines, including U87 and U251, into the zebrafish brain. Transgenic zebrafish with labeled macrophages/microglia were used for live confocal imaging of tumor–immune cell interactions. The model allowed direct visualization of differential microglial responses toward distinct GBM cell lines in vivo.

Fig. 1. Live imaging shows microglia/macrophage recruitment and interaction with intracranial glioblastoma xenografts in zebrafish larvae (Hamilton L, Astell KR, et al., 2016).

The study generated a syngeneic zebrafish GBM-like model by introducing clinically relevant oncogenic alterations, including tp53 deficiency, EGFRvIII expression, and activated PI3K signaling, into the developing zebrafish brain. The resulting tumors showed features consistent with human glioblastoma biology and were used to study tumor initiation, progression, relapse, and host inflammatory responses in vivo.

Fig. 2. Combined tp53 loss, EGFRvIII expression, and PI3K activation drive GBM-like tumor formation in zebrafish (Weiss A, D'Amata C, et al., 2024).

Accelerate Glioblastoma Research with Zebrafish Models

Accelerate your glioblastoma research with validated zebrafish GBM models for in vivo efficacy testing, tumor invasion analysis, angiogenesis assessment, and microenvironment studies.

Contact Our Scientists

References

Hamilton L, Astell KR, et al. A Zebrafish Live Imaging Model Reveals Differential Responses of Microglia Toward Glioblastoma Cells In Vivo. Zebrafish. 2016;13(6):523–534.
Weiss A, D'Amata C, et al. A syngeneic spontaneous zebrafish model of tp53-deficient, EGFRvIII, and PIK3CAH1047R-driven glioblastoma reveals inhibitory roles for inflammation during tumor initiation and relapse in vivo. eLife. 2024;13:RP93077.

For research use only. Not intended for any clinical use.